Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / United Kingdom

European Research Council grant · Running

BrokenChromosomes Decoding tumour-immune interactions and the evolutionary trajectories of complex genomic rearrangements in highly aggressive cancers

Coordinator
The Chancellor, Masters and Scholars of the University of Oxford, United Kingdom
Runs
1 October 2026 to 30 September 2031
Status
Running
EU funding
€2.0m
Total cost
€2.0m
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101231997

What the project is doing

In the project's own words, from its summary on CORDIS.

Cancer genomes are riddled by remarkably complex forms of structural variants collectively known as complex genomic rearrangements (CGRs). Our previous work showed that CGRs occur at high frequency in some of the deadliest cancers in humans and underpin drug resistance and poor prognosis. Yet, the impact of CGRs on immune escape, cancer cell plasticity, metastasis, drug resistance and clonal evolution remains elusive.

As a result, we have not been able to deliver eagerly awaited breakthroughs for the treatment of tumours driven by CGRs. In this ERC project, I aim to change the paradigm for cancer therapy development for tumours driven by CGRs. To this aim, BrokenChromosomes will first rely on a multi-disciplinary approach combining spatially resolved multi-omic profiling of tumours to elucidate the mechanisms whereby CGRs shape the tumour-immune microenvironment to achieve immune escape and modulate cancer cell fitness and plasticity during tumour evolution and metastatic spread, which might open new therapeutic avenues to treat currently incurable cancers driven by CGRs.

Second, we will study the differentiation dynamics and phenotypes of neoantigen-specific tumour-infiltrating T cells in tumours showing high rates of CGRs, and we will assess their tumour-killing activity using patient-derived ex vivo tumour-immune co-cultures. By assessing the immunogenicity of diverse mutations in tumours driven by CGRs, I aim to provide critical new knowledge to enable the development of therapeutic breakthroughs for these tumours using immunotherapies.

Finally, we will decode the interplay between epigenetic dysregulation at centromeres, chromosomal instability and CGR formation, which might also have far-reaching implications beyond cancer by explaining why e.g., increased rates of aneuploidy in healthy cells, e.g. oocytes, is an age-dependent process.

Topics

Who is involved

OrganisationCityCountryRole
The Chancellor, Masters and Scholars of the University of OxfordOxfordUnited KingdomCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI